Research programme: G-protein coupled receptor modulators - Ogeda/Novartis

Drug Profile

Research programme: G-protein coupled receptor modulators - Ogeda/Novartis

Alternative Names: GPCR therapeutics - Ogeda/Novartis

Latest Information Update: 18 May 2017

Price : $50

At a glance

  • Originator Euroscreen; Genomics Institute of the Novartis Research Foundation; Novartis
  • Developer Novartis; Ogeda
  • Class Small molecules
  • Mechanism of Action G protein-coupled receptor modulators; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Immunological disorders

Most Recent Events

  • 16 May 2017 Ogeda has been acquired by and became a wholly-owned subsidiary of Astellas Pharma
  • 19 Oct 2016 Euroscreen is now called Ogeda
  • 12 Sep 2011 Research is ongoing in Belgium
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top